Cellectis Received Proceeds of €13 Million Through The Exercise Of Warrants

PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA), a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART cells (UCART), announces that it has received €13,237,524 ($16.5M) through the exercise of 7,354,180 warrants of the 12,195,113 warrants issued in October 2011, which expired on October 28, 2014 (60.3% of the total amount).

Help employers find you! Check out all the jobs and post your resume.